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PLASMA METABOLOME OF CHILDREN WITH ABERRANT CHOLESTEROL AND 
MODULATION BY NAVY BEAN AND RICE BRAN CONSUMPTION  
 
 
Abnormal cholesterol in childhood predicts cardiovascular disease (CVD) risk in 
adulthood. Navy beans and rice bran have demonstrated efficacy in regulating blood lipids in 
adults and children; however, their effects on modulating the child plasma metabolome has not 
been investigated and warrants investigation. A pilot, randomized-controlled, clinical trial was 
conducted in 38 children (10 ± 0.8 years old) with abnormal cholesterol. Participants consumed a 
snack for 4 weeks containing either: no navy bean or rice bran (control); 17.5 g/day cooked navy 
bean powder; 15 g/day heat-stabilized rice bran, or; 9 g/day navy beans and 8 g/day rice bran. 
Plasma metabolites were extracted using 80% methanol for global, non-targeted metabolic 
profiling via ultra-high performance liquid-chromatography tandem mass spectrometry. To 
examine correlations between baseline serum lipid levels and plasma metabolites, non-
parametric Spearman’s correlation coefficients (rs) were computed between serum total 
cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol, and triglycerides (TG) with 805 plasma metabolites. Differences in plasma 
metabolite levels after 4 weeks of dietary intervention compared to control and baseline were 
analyzed using analysis of variance and Welch’s t-tests (p≤0.05). Approximately 29% of the 
plasma metabolome (235 metabolites) were significantly correlated with serum lipids. Plasma 
cholesterol was positively correlated with serum total cholesterol, and 27 plasma metabolites 
were found to be strongly correlated with serum TG (rs ≥0.60; p≤0.0001). Navy bean and/or rice 
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bran consumption influenced 71 plasma compounds compared to control (p≤0.05), with lipids 
representing 46% of the total plasma metabolome. Significant changes were determined for 18 
plasma lipids in the navy bean group and 10 plasma lipids for the rice bran group compared to 
control, and 48 lipids in the navy bean group and 40 in the rice bran group compared to baseline. 
This supports the hypothesis that consumption of these foods impact blood lipid metabolism with 
implications for reducing CVD risk in children. Complementary and distinct lipid pathways were 
affected by the diet groups, including acylcarnitines and lysolipids (navy bean), sphingolipids 
(rice bran), and phospholipids (navy bean + rice bran). Navy bean consumption decreased free 
fatty acids associated with metabolic diseases (palmitate and arachidonate) and increased the 
relative abundance of endogenous anti-inflammatory lipids (endocannabinoids, N-
linoleoylglycine, 12,13-diHOME). Several diet-derived amino acids, phytochemicals, and 
cofactors/vitamins with cardioprotective properties were increased compared to control and/or 
baseline, including 6-oxopiperidine-2-carboxylate (1.87-fold), N-methylpipecolate (1.89-fold), 
trigonelline (4.44- to 7.75-fold), S-methylcysteine (2.12-fold) (navy bean), salicylate (2.74-fold), 
and pyridoxal (3.35- to 3.96-fold) (rice bran). Findings from this pilot study support the need for 
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Cardiovascular disease (CVD) is the leading cause of death in the United States (U.S.) 
and globally (1). Childhood and adolescence marks a critical period for the emergence of CVD 
risk factors, and several epidemiological studies have indicated that abnormal cholesterol levels 
early in life predicts atherosclerosis and CVD later in life (2-7). Data from the National Health 
and Nutrition Examination Survey 2011-2014 reveals that approximately 21% of children and 
adolescents in the U.S. have at least one abnormal serum cholesterol measure (8, 9). In addition, 
histopathological evidence for atherosclerosis has also been found in the arterial walls of 
children as young as 3 years old (10). A compelling rationale exists to sustainably control blood 
lipids during childhood to prevent or delay the development of life-threatening cardiovascular 
events later in life.  
Lifestyle modifications in diet and physical activity can protect against CVD across the 
lifespan, and plant-based diets high in stanols/sterols and soluble fiber have been recognized by 
the National Cholesterol Education Program as an important strategy to reduce or control 
cholesterol (9, 11). Proper nutrition in childhood can lend long-term protection against multiple 
risk factors for CVD not only via controlling blood lipids, but also by regulating the underlying 
cellular processes that drive metabolic diseases. Metabolic signatures associated with early signs 
of CVD can also be useful for personalized medicine initiatives in the diagnosis and profiling of 
disease phenotypes, and enhance standard CVD risk prediction models (12-14). Metabolomics is 
an emerging tool for dietary intervention trials and pediatric research that provides insight into 
the complex relationships between dietary exposures, host digestion and gut microbial 
metabolism (13, 15-18). Through non-targeted metabolomics approaches, all metabolites (in 
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theory) within a biological sample can be identified in a non-biased manner, to reveal novel 
insights and biomarkers (19).  
Cooked dry beans (a legume) and rice bran (a whole grain component) are rich sources of 
proteins, lipids, vitamins, fiber, and phytochemicals that have favorable impacts on intestinal and 
cardiovascular health (20-24). Increased consumption of navy beans and rice bran have 
demonstrated efficacy in lowering serum cholesterol levels in experimental animals (25, 26),  
hypercholesterolemic adults (21, 27, 28), as well as modulating high-density lipoprotein (HDL) 
and low-density lipoprotein (LDL) cholesterol in some children after 4 weeks of consumption 
(29). However, the effects of navy bean and rice bran consumption on the plasma metabolome of 
children with abnormal cholesterol have not been previously evaluated. A global, non-targeted 
metabolomics analysis was applied to characterize the plasma metabolome of children with 
aberrant cholesterol, and to reveal the network of metabolic pathways altered by 4 weeks of daily 
intake with navy bean, rice bran, or a combination of navy bean + rice bran when compared to a 
control at 4 weeks, or compared to their respective baseline. We hypothesized that navy bean and 
rice bran consumption favorably modulates multiple metabolic pathways associated with 
cholesterol-lowering in children. Identification of bioactive food compounds with 
cardioprotective properties will elucidate important mechanisms by which navy beans and rice 









2.1  Study Participants 
Healthy children aged 8-13 years old were recruited from a school-based program 
(Healthy Hearts) in Northern Colorado, as previously described (29, 30). These children 
underwent cholesterol screening and were included on the basis of having abnormal cholesterol 
levels that put them at high risk for future CVD. Criteria for abnormal cholesterol included 
either: total cholesterol ≥180 mg/dL and HDL <60 mg/dL; LDL ≥100 mg/dL and HDL <60 
mg/dL; or non-HDL >100 mg/dL and HDL <60 mg/dL. Children with ongoing medical illnesses, 
taking medications, or with food allergies or major dietary restrictions, were excluded from 
participation. Study protocols were approved by the University of Colorado Health-North 
Institutional Review Board (Protocol 13-1263) and the Colorado State University Research 
Integrity and Compliance Review Office (Protocol 13-4390). Prior to the start of the trial, written 
informed consent were obtained from guardians and written informed assent from all participants 
in accordance with the Declaration of Helsinki. This trial was registered at clinicaltrails.gov 
under NCT01911390. 
 
2.2  Dietary Interventions 
Eligible participants were computer-randomized by sex into one of four dietary 
intervention groups. All participants received a muffin or smoothie daily for 4 weeks that had (1) 
no navy beans or rice bran (control, 0g/day), (2) 17.5 g/day cooked navy beans, (3) 15 g/day 
heat-stabilized rice bran, or (4) a combination of 9 g/day navy bean and 8 g/day rice bran 
(Figure 1). The amounts of navy bean and/or rice bran in the navy bean, rice bran, and navy 
bean + rice bran groups provided 55, 48, and 53 kcal/day, respectively (29). Study-provided 
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foods were coded to ensure participant blinding. Cooked navy bean powder (VegeFull™) was 
provided by Archer Daniels Midland Edible Bean Specialties, Inc. (Decatur, IL), and heat-
stabilized rice bran was provided by the U.S. Department of Agriculture-Agricultural Research 
Service Dale Bumpers National Rice Research Center (Stuttgart, AR). All study foods were 
prepared in a commercial kitchen with quality control measures at Colorado State University as 
previously described (29). 
 
Figure 1. Participants in each dietary intervention group and the plasma samples used for metabolome 
analysis. CONSORT diagram shown in Borresen et al. (27). Reasons for withdrawal included: noncompliance to 
the study protocol (n = 5), declined to participate (n = 6), and gastrointestinal issues (n = 1). 
 
 
2.3  Blood Sample Collection 
Fasting blood samples were collected from the participants by venipuncture at baseline 
and week 4.  Blood samples were collected into 4 mL sodium citrate cell preparation tubes (BD 
Biosciences, Franklin Lakes, NJ) and centrifuged at 1,500 relative centrifugal force at room 
temperature for 30 minutes to separate red and white cells from plasma. The serum lipid panel 
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comprised total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides (TG) (29). 
Plasma was aliquoted (0.5 mL) and frozen at -80°C until metabolomics analysis.  
 
2.4  Plasma Metabolite Extraction, Identification and Metabolome Analysis 
Metabolon, Inc (Durham, NC) performed plasma metabolite extraction and non-targeted 
global metabolic profiling on all samples via ultra-high performance liquid-chromatography 
tandem mass spectrometry (UPLC-MS/MS). Data were accessioned into Metabolon’s Library 
Information Management System and assigned a unique identifier associated with the participant 
study codes that tracked all clinical trial information.  
Plasma was prepared using the automated MicroLab STAR® system (Hamilton 
Company). To remove protein and recover small molecules, the sample was precipitated with 
methanol and vigorously shaken for 2 minutes (Glen Mills GenoGrinder 2000) followed by 
centrifugation. The resulting extract was analyzed by reverse phase UPLC-MS/MS with positive 
and negative ion mode electrospray ionization and hydrophilic interaction liquid chromatography 
(HILIC) with negative ion mode electrospray ionization. Extracts were placed briefly on a 
TurboVap® (Zymark) automated evaporation system to remove remaining organic solvent and 
stored in liquid nitrogen prior to analysis. 
UPLC-MS/MS was completed using a Waters ACQUITY UPLC and a Thermo Scientific 
Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray 
ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The 
dried sample was reconstituted in solvents containing a series of standards at fixed 
concentrations. Extracts were analyzed using acidic positive ion conditions optimized for 
hydrophilic or hydrophobic compounds by gradient eluting from a dedicated C18 column 
(Waters UPLC BEH C18-2.1x100 mm, 1.7 µm) using water, methanol, 0.05% 
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perfluoropentanoic acid, and 0.1% formic acid (hydrophilic), or methanol, acetonitrile, water, 
0.05% perfluoropentanoic acid, and 0.01% formic acid (hydrophobic). A basic negative ion 
extract was gradient eluted from a separate C18 column using methanol, water, and 6.5 mM 
ammonium bicarbonate at pH 8, and the remaining extract was analyzed via negative ionization 
following gradient elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 
µm) using water, acetonitrile, and 10 mM ammonium formate at pH 10.8. The MS analysis 
alternated between MS and data-dependent MSn scans using dynamic exclusion (70 to 1000 m/z).  
Raw data was extracted and peak-identified by Metabolon. Identity of the compounds 
were confirmed by comparison to an internal library of over 3,300 entries of purified standards 
or recurrent unknown entities maintained by Metabolon, based on the retention time/index, m/z, 
and chromatographic data. Metabolites were quantified in terms of relative abundance and a 
scaled relative abundance was calculated for each metabolite by dividing its raw abundance by 
the median value of the metabolite across the dataset. Metabolite ratios were calculated by 
dividing the median-scaled abundance of each metabolite in the navy bean, rice bran and navy 
bean + rice bran groups at 4 weeks by that of the control group at 4 weeks, or by their respective 
baseline at week 0, to identify metabolites that were significantly different between groups (fold-
differences) or within groups (fold-changes). 
 
2.5  Food Metabolite Extraction and Identification 
Non-targeted metabolomics on the navy bean powder and heat-stabilized rice bran (each 
100 mg) was performed by Metabolon. Food metabolites were extracted with 80% methanol and 
analyzed by UPLC-MS/MS and gas-chromatography mass-spectrometry (GC-MS) in the 
positive and negative ionization mode platforms. UPLC-MS/MS was performed using the same 
methods as described above. For GC-MS, the food extracts were derivatized under nitrogen 
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using bistrimethyl-silyltrifluoroacetamide and separated on a 5% diphenyl/95% dimethyl 
polysiloxane-fused silica column (20 m x 0.18 mm ID; 0.18 μm film thickness) using helium as 
carrier gas and a temperature ramp from 60°C to 340°C in a 17.5 minute period. Internal 
standards (250 ng each of amylbenzene, 1-phenylhexane, 1-phenyloctane, 1-phenyldecane, 1-
phenyldodecane, hexadecylbenzene, octadecylbenzene, tetradecylbenzene and 2,6-di-tert-butyl-
4-methylphenol) were added to each sample. Samples were analyzed on a Thermo-Finnigan 
Trace DSQ fast-scanning single-quadrupole mass spectrometer using electro impact ionization 
(EI) and operated at unit mass resolving power (scan range 50 to 750 m/z). Raw data were peak-
identified as described above and raw counts of each metabolite were quantified using area-
under-the-curve. 
To ascertain whether metabolites identified in plasma could be of dietary origin 
(exclusively or in part), the full list of plasma metabolites identified in each dietary group after 4 
weeks of consumption was cross-referenced with metabolites identified in the food metabolome. 
 
2.6  Metabolic Pathway Visualizations 
Metabolic pathway visualizations were generated using the Metabolync™ plug-in for 
Cytoscape (Version 2.8.3). Pathway enrichment scores for metabolic subpathways were 
calculated using the following equation, where k represents the number of significant metabolites 
in a pathway, m represents the total number of identified metabolites in that pathway, n 
represents the total number of significant metabolites in the complete dataset, and N represents 






Pathways with enrichment scores greater than one indicated that the metabolic pathway 
contained a higher number of metabolites with statistically significant fold-differences or fold-
changes compared to other pathways in the study. 
 
2.7  Statistical Analysis 
Power calculation for this pilot study was based on effect sizes reported in a previous rice 
bran dietary intervention metabolomics study (31, 32). To determine correlations between 
plasma metabolites and serum lipid levels, non-parametric Spearman’s rank-order coefficients 
(rs) were calculated between each type of serum lipid (total cholesterol, LDL, HDL, and TG) and 
the median-scaled relative abundance for each identified plasma metabolite at baseline for all 
children. All correlations were performed using GraphPad Prism (Version 7). From all 
significant correlations determined, a cut-off of rs≥0.60 and p≤0.0001 was applied to isolate 
strong correlations. To determine the effect of dietary intervention on plasma metabolome 
modulation, two-way analysis of variance (ANOVA) and Welch’s two-sample t-tests were used 
to determine statistical significance between groups, and ANOVA with repeated measures was 
used to determine statistical significance within groups (p≤0.05). Metabolites that showed 
statistical difference at baseline between navy bean, rice bran, or navy bean + rice bran groups 
and control were removed from the between-group analyses (39 metabolites removed in total). 
An estimate of the false discovery rate was calculated (q-value) to take into account the multiple 








3.1  Baseline serum lipid levels and plasma metabolome of study participants 
Serum lipid levels in the 38 children ranged from 128 to 255 mg/dL for total cholesterol, 
67 to 198 mg/dL for LDL-cholesterol, 31 to 58 mg/dL for HDL-cholesterol, and 46 to 197 
mg/dL for TG (Fig 2a). Nine (9) participants had total cholesterol levels higher than 180 mg/dL, 
20 participants had high LDL-cholesterol levels higher than 100 mg/dL, and all 38 participants 
had HDL-cholesterol levels below 60 mg/dL, the latter of which are study inclusion cut-off 
values for abnormal cholesterol (a cut-off value for elevated TG was not applied in the study 
inclusion criteria). The diversity in the plasma metabolome profiles across the 38 study 
participants is visualized in Fig 2b, with a high level of consistency observed for some 
metabolites across all participant profiles. Out of 805 metabolites identified at baseline, 
metabolites with highest median-scaled relative abundance (top 1% of data) compared to all 
other metabolites included 5 lipids (carnitine, the long-chain fatty acids oleate/vaccinate, 
palmitate, and stearate, and the polyunsaturated fatty acid linoleate), 1 amino acid (glutamine) 
and 1 energy cycle metabolite (citrate). High relative abundance (top 10% of data) was also 
observed for 35 lipids, 23 amino acids, 3 carbohydrates, 1 cofactor/vitamin, 1 nucleotide, and 1 
xenobiotic/phytochemical (data not shown). Metabolites with lowest median-scaled relative 
abundance (bottom 1% of data) compared to all other metabolites identified in plasma included 3 
amino acids (o-cresol sulfate, xanthurenate, 5-hydroxyindoleacetate), 1 cofactor/vitamin (alpha-
CEHC sulfate), 1 nucleotide (N6-succinyladenosine), 1 peptide (phenylacetylglutamate), and 1 
xenobiotic/phytochemical [N-(2-furoyl)glycine]. Metabolites in the bottom 10% of relative 
abundance included 26 lipids, 18 amino acids, 11 xenobiotics/phytochemicals, 6 nucleotides, 1 






       
 
 
Figure 2. Serum lipid levels and plasma metabolome of 38 study participants. (a) Levels of total cholesterol, 
LDL-cholesterol, HDL-cholesterol, and TG in all study participants. Dotted lines represent study inclusion criteria 
cut-offs for total, LDL-, and HDL-cholesterol. (b) Normalized plasma metabolic profiles for all study participants, 
including 805 plasma metabolites identified at baseline, across 8 metabolic classes (median = 1). 
Amino Acids Carbohydrates Cofactors/Vitamins Energy
Lipids Nucleotides Peptides Xenobiotics
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3.2  Plasma metabolites correlated with serum lipids at baseline 
Of the 805 metabolites detected and identified in plasma at baseline, significant 
correlations to serum lipids (p≤0.05) were determined for 235 compounds (29% of the plasma 
metabolome), including 157 lipids, 35 amino acids, 13 xenobiotics, 13 peptides, 7 carbohydrates, 
7 nucleotides, 2 cofactors/vitamins, and 1 energy cycle metabolite. Twenty-eight (28) plasma 
metabolites were found to be strongly correlated with serum lipids (rs≥0.60; p≤0.0001), and 
warranted greater attention. As expected, plasma cholesterol was strongly positively correlated 
with serum total cholesterol (rs = 0.6654, CI=0.4312 to 0.8156; p<0.0001). The remaining 27 
compounds were correlated with serum TG (Table 1). One plasmalogen [1-(1-enyl-palmitoyl)-2-
oleoyl-glycerophosphocholine] was determined to be negatively correlated with serum TG (rs = -
0.6806; p<0.0001), and 3 phospholipid metabolites (1-palmitoyl-2-arachidonoyl-
glycerophosphoethanolamine, 1-palmitoyl-2-linoleoyl-glycerophosphoethanolamine, and 1-
stearoyl-2-linoleoyl-glycerophosphoethanolamine) were determined to be positively correlated to 
serum TG (rs = 0.6281 to 0.7309; p<0.0001). In addition, 68.8% of plasma diacylglycerols 
identified were strongly correlated with serum TG (rs = 0.6033 to 0.882; p<0.0001). One plasma 
amino acid, alanine, was positively correlated with serum TG (rs = 0.6242; p<0.0001). 
 
Table 1      Plasma Metabolites Strongly Correlated (rs ≥0.60, p<0.0001) with Serum  
                   Triglycerides in Children at Baseline 
Subpathway Metabolite Spearman’s Correlation Coefficient 
rs 95% CI 
Amino Acids 
Alanine & Aspartate 
Metabolism 
alanine 0.6242 0.372 to 0.7906 
Lipids 
Plasmalogen 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1) -0.6806 -0.8247 to -0.4535 
Phospholipid 
Metabolism 
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) 0.6412 0.3961 to 0.8009 
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) 0.6281 0.3776 to 0.793 
1-stearoyl-2-linoleoyl-GPE (18:0/18:2) 0.7309 0.5296 to 0.8543 
Diacylglycerol diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2] 0.7975 0.6355 to 0.8922 
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diacylglycerol (14:0/18:1, 16:0/16:1) [1] 0.836 0.6997 to 0.9136 
diacylglycerol (14:0/18:1, 16:0/16:1) [2] 0.7833 0.6123 to 0.8842 
diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1]) 0.7926 0.6274 to 0.8895 
linoleoyl-linolenoyl-glycerol (18:2/18:3) [1] 0.627 0.376 to 0.7923 
linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] 0.6315 0.3824 to 0.7951 
linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] 0.6033 0.3428 to 0.7776 
oleoyl-linoleoyl-glycerol (18:1/18:2) [1] 0.8187 0.6706 to 0.9041 
oleoyl-linoleoyl-glycerol (18:1/18:2) [2] 0.8092 0.6548 to 0.8988 
oleoyl-oleoyl-glycerol (18:1/18:1) [2] 0.882 0.7793 to 0.9386 
oleoyl-oleoyl-glycerol (18:1/18:1) [1] 0.8605 0.7417 to 0.927 
palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1] 0.7572 0.5707 to 0.8694 
palmitoleoyl-oleoyl-glycerol (16:1/18:1) [1] 0.6459 0.4029 to 0.8038 
palmitoleoyl-oleoyl-glycerol (16:1/18:1) [2] 0.665 0.4306 to 0.8154 
palmitoyl-linolenoyl-glycerol (16:0/18:3) [2] 0.7017 0.485 to 0.8372 
palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] 0.7086 0.4955 to 0.8413 
palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] 0.8143 0.6633 to 0.9016 
palmitoyl-myristoyl-glycerol (16:0/14:0) [2] 0.7113 0.4995 to 0.8428 
palmitoyl-oleoyl-glycerol (16:0/18:1) [1] 0.8404 0.7071 to 0.916 
palmitoyl-oleoyl-glycerol (16:0/18:1) [2] 0.8603 0.7414 to 0.9269 
palmitoyl-palmitoyl-glycerol (16:0/16:0) [1] 0.6837 0.4581 to 0.8265 
palmitoyl-palmitoyl-glycerol (16:0/16:0) [2] 0.7418 0.5464 to 0.8606 
CI, confidence interval; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine. 
 
3.3 Effects of navy bean and/or rice bran on modulating the nutritional metabolome of 
children at risk for cardiovascular disease 
Thirty-eight children (10 ± 0.8 years old) enrolled and randomized to a dietary 
intervention successfully completed the trial and were analyzed for changes in the plasma 
metabolome (Figure 1). Across the 4 dietary interventions, a total of 854 metabolites from 8 
chemical classes were identified in plasma, of which 397 were classified as lipids, 183 amino 
acids, 143 phytochemicals, 38 nucleotides, 32 cofactors/vitamins, 30 peptides, 23 carbohydrates, 
and 8 energy pathway metabolites (Figure 3a). Navy bean and/or rice bran consumption resulted 
in statistically significant modulation of metabolites from all 8 metabolic pathway classifications 
(p≤0.05) (Figure 3bc). Compared to control at week 4, the total number of significantly altered 
metabolites in each diet group were 34 (navy bean), 24 (rice bran), and 18 (navy bean + rice 
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bran) (Figure 3b). Compared to their respective baseline, the total number of significantly 
altered plasma metabolites were 49 (control), 75 (navy bean), 104 (rice bran), and 37 (navy bean 
+ rice bran) (Figure 3c). Lipid, amino acid, and phytochemical pathways contained the largest 
total number of significantly modulated metabolites, with comparatively fewer significant 





Figure 3. Nutritional metabolome of children modulated by navy bean and/or rice bran consumption. (a) 
Total metabolite profile identified from plasma of children across all dietary groups. Total numbers of significantly 
modulated metabolites (increased and decreased, p≤0.05) across eight metabolite classes after 4 weeks of 
navy bean, rice bran, or navy bean + rice bran consumption (b) compared to control group at 4 weeks or (c) 
compared to respective baseline. 
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3.4  Differences in plasma lipid metabolites following navy bean and/or rice bran 
consumption 
Consumption of navy bean and/or rice bran resulted in a global increase in lipid 
metabolites compared to control at 4 weeks (Table 2). Submetabolic pathways of lipids 
modulated by navy bean and/or rice bran consumption were distinct and complementary, as 
shown in Table 2 and visualized in Figure 4a,c,e. Navy bean consumption significantly 
increased 18 lipids compared to control at 4 weeks, including 4 acylcarnitine (1.37- to 1.47-fold 
difference), 4 lysolipid (1.21- to 1.45-fold difference), and 2 ceramide (1.24- to 1.28-fold 
difference) pathway metabolites (Table 2). Significant increases in several plasmalogens, 
acylglycines, phospholipids, dicarboxylate fatty acids, and sphingolipids were also determined. 
Rice bran consumption significantly increased 10 lipids compared to control at 4 weeks, 
including 4 sphingolipid metabolites (1.28- to 1.42-fold difference), 3 ceramide metabolites 
(1.28- to 1.42-fold difference), the secondary bile acid glychodeoxycholate sulfate (4.37-fold 
difference), as well as several phospholipid and monohydroxy fatty acids (Table 2). 
Consumption of navy bean + rice bran significantly increased 7 lipids compared to control at 4 
weeks, which included 3 lysolipid metabolites (1.39- to 1.90-fold difference), 3 phospholipid 
metabolites (1.21- to 1.54-fold difference), and the endocannabinoid N-oleoyltaurine (2.15-fold 
difference) (Table 2). One lipid metabolite (carnitine) was decreased following navy bean + rice 
bran consumption compared to control at 4 weeks. Overall, fewer lipid metabolites were affected 





Table 2    Modulated Plasma Lipid Metabolites Following Navy Bean and/or Rice Bran 
Consumption for 4 Weeks Compared to Controla 
Metabolic Subpathway Metabolite Fold-Difference vs. Controlb 
Navy Bean Rice Bran Navy Bean 
+ Rice Bran 
Fatty Acid, Dicarboxylate 
2-hydroxyglutarate 1.32↑* 1.02 1.12 
eicosanodioate 1.63↑* 1.09 1.27 
Fatty Acid Metabolism 
(Acyl Glycine) 
N-linoleoylglycine 2.05↑* 1.39 1.72 
Fatty Acid Metabolism 
(Acyl Carnitine) 
arachidoylcarnitine 1.47↑* 1.17 1.24 
behenoylcarnitine 1.44↑* 1.12 1.22 
lignoceroylcarnitine 1.40↑* 1.19 1.21 
cerotoylcarnitine 1.37↑** 1.22 1.27 
Carnitine Metabolism carnitine 0.93 0.92 0.87↓* 
Fatty Acid, Monohydroxy 2-hydroxydecanoate 1.22 1.70↑* 1.26 
Endocannabinoid N-oleoyltaurine 1.60 1.36 2.15↑* 
Phospholipid Metabolism 
1-palmitoyl-2-oleoyl-GPC 1.17 1.16↑* 1.24 
1-stearoyl-2-oleoyl-GPC 1.18 1.13 1.21↑* 
1-palmitoyl-2-palmitoleoyl-GPC 1.16 1.15 1.54↑** 
1-palmitoyl-2-oleoyl-GPI 1.06 1.21 1.51↑* 
1-palmitoleoyl-2-linolenoyl-GPC 1.35↑* 1.14 1.52 
Lysolipid 
1-palmitoyl-GPC 1.21↑* 1.14 1.19 
1-palmitoleoyl-GPC 1.35↑* 1.21 1.39↑* 
1-linolenoyl-GPC 1.45↑** 1.04 1.42 
1-palmitoyl-GPE 1.33↑* 1.07 1.26 
1-palmitoyl-GPG 1.09 1.09 1.75↑* 
1-linoleoyl-GPG 1.26 1.33 1.90↑* 
Plasmalogen 
1-(1-enyl-palmitoyl)-2-oleoyl-GPC 1.28↑* 1.13 1.15 




1.15 1.30↑** 1.19 
N-behenoyl-sphingadienine 
(d18:2/22:0) 
1.28↑* 1.37 1.15 
sphingomyelin (d18:1/15:0, 16:1/17:0) 1.13 1.28↑** 1.10 
N-palmitoyl-sphingosine (d18:1/16:0) 1.23 1.42↑** 1.37 
N-stearoyl-sphingosine (d18:1/18:0) 1.13 1.33↑* 1.12 
glycosyl-N-behenoyl-sphingadienine 
(d18:2/22:0) 
1.25↑* 1.18 1.19 
Secondary Bile Acid 
Metabolism 
glycodeoxycholate sulfate 5.70 4.37↑* 4.12 
Ceramides 
ceramide (d18:1/14:0, d16:1/16:0) 1.12 1.37↑** 1.23 
ceramide (d18:1/17:0, d17:1/18:0) 1.11 1.42↑** 1.10 
ceramide (d18:1/20:0, d16:1/22:0, 
d20:1/18:0) 
1.28↑* 1.32 1.17 
ceramide (d18:2/24:1, d18:1/24:2) 1.12 1.28↑* 1.17 
glycosyl ceramide (d18:1/20:0, 
d16:1/22:0) 
1.24↑* 1.30 1.32 
GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; GPG, glycerophosphoglycerol; GPI, 
glycerophosphoinositol. aMetabolites that were detected in plasma but non-significant (p>0.05) in dietary groups 
compared to respective baseline are not presented in this table. bValues presented are mean metabolite ratios/fold-
differences. Statistically-significantly increased (↑) fold-differences are bolded and highlighted in red, and 









Figure 4. Cytoscape pathway visualizations of lipid metabolites modulated by navy bean, rice bran, or navy 
bean + rice bran consumption. Lipid metabolites modulated by navy bean, rice bran, or navy bean + rice bran 
consumption for 4 weeks compared to control is shown in panels a,c,e respectively. Lipid metabolites 
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modulated by navy bean, rice bran, or navy bean + rice bran consumption for 4 weeks compared to respective 
baseline is shown in panels b,d,f respectively. Nodes in red and blue represent significantly increased and decreased 
metabolites, respectively, compared to control or baseline (p ≤ 0.05). For each metabolite, the node diameter is 
proportional to the magnitude of the fold difference/change. Numerical values within nodes indicate the calculated 
pathway enrichment score. Pathways with enrichment scores greater than 1 were defined as being important 
contributors to overall dietary group differences (visualized in red/yellow). 
 
Numerous lipid metabolites were also significantly modulated by each of the dietary 
groups at 4 weeks compared to their respective baseline, with the largest effect observed in the 
navy bean group (48 significantly modulated lipid metabolites) (Table 3). Similar to the 
between-group analyses, submetabolic pathways of lipids affected by navy bean and/or rice bran 
consumption compared to their baseline levels were distinct and complementary (Figure 4b,d,f). 
Table 3 reveals that navy bean consumption decreased 44 lipids and increased 4 lipids compared 
to baseline. Lipids with decreased relative abundance included 14 long chain fatty acids (0.63- to 
0.80-fold change), 8 polyunsaturated fatty acids (0.66- to 0.86-fold change), 6 acyl carnitines 
(0.75- to 0.84-fold change), 4 monohydroxy fatty acids (0.72- to 0.82-fold change), 3 branched 
fatty acids (0.63- to 0.70-fold change), along with several endocannabinoid, monoacylglycerol, 
lysolipid, sterol, dicarboxylate fatty acid, and acyl glycine metabolites. Lipids with increased 
relative abundance included the dicarboxylate fatty acid adipate (1.12-fold change), the 
dihydroxy fatty acid 12,13-DiHOME (1.36-fold change), the phospholipid 1-linoleoyl-2-
linolenoyl-GPC (18:2/18:3) (2.11-fold change), and the secondary bile acid metabolite 
glycodeoxycholate (4.27-fold change). Following rice bran consumption, significant decreases in 
12 and increases in 28 lipid metabolites were determined compared to baseline (Table 3). 
Classes of modulated lipid metabolites included decreases in 4 acyl carnitines (0.65- to 0.89-fold 
change) and 4 sphingolipids (all 0.91-fold change), and increases in 7 sphingolipids (1.19- to 
1.55-fold change), 6 steroids (1.20- to 1.52-fold change), 4 diacylglycerols (1.88- to 4.44-fold 
change), 3 primary bile acids (taurocholate; 1.54-fold change, taurochenodeoxycholate; 3.65-fold 
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change, and tauro-beta-muricholate; 2.29-fold change) and a secondary bile acid 
(glycodeoxycholate; 1.10-fold change). For the navy bean + rice bran group, 9 lipid metabolites 
were decreased compared to baseline, including 2 ceramides (0.87- to 0.90-fold change), the 
primary bile acid glycocholate glucuronide (0.93-fold change change), and singular decreases in 
acyl carnitine, ketone body, phosholipid, monoacylglycerol, sphingolipid, and acyl choline 
metabolites. Of the suite of 9 metabolites increased following consumption of navy bean + rice 
bran compared to baseline, the most notable includes an increase in 4 diacylglyerols (2.70- to 
8.03-fold change) and the primary bile acid taurochenodeoxycholate (2.81-fold change). Several 
increases in medium chain fatty acid, phospholipid, and lysolipid metabolites were also 
determined (Table 3). Interestingly, comparison of the control group at 4 weeks to its respective 
baseline also revealed 22 decreased and 3 increased lipid metabolites, including 6 
polyunsaturated fatty acids (0.64- to 0.79-fold change), 5 monoacylglycerols (0.71- to 0.85-fold 
change), 6 steroids (0.73- to 0.85-fold change), and modulations in several acylcarnitine, 





Table 3    Modulated Plasma Lipid Metabolites Following Navy Bean and/or Rice Bran Consumption for 4 Weeks 
Compared to Baselinea 
Metabolic Subpathway Metabolite Fold-Change vs. Baselineb 
Control Navy Bean Rice Bran Navy Bean + 
Rice Bran 
Medium Chain Fatty Acid caproate 1.05 1.00 0.96 1.17↑* 
Long Chain Fatty Acid 
myristate 0.91 0.70↓* 1.47 1.09 
myristoleate 1.03 0.69↓* 1.56 1.39 
pentadecanoate 0.85 0.76↓** 1.18 0.94 
palmitate 0.91 0.74↓** 1.19 0.90 
palmitoleate 0.90 0.72↓* 1.64 1.27 
margarate 0.78 0.63↓** 1.25 0.89 
10-heptadecenoate 0.85 0.66↓* 1.47 1.02 
stearate 0.89 0.76↓** 1.08 0.91 
nonadecanoate 0.88 0.71↓** 1.14 0.95 
10-nonadecenoate 0.79 0.64↓** 1.20 0.89 
arachidate 0.86 0.80↓** 0.99 0.98 
eicosenoate 0.84 0.68↓** 1.13 0.88 
erucate 0.77 0.73↓* 0.91 1.23 
oleate/vaccenate  0.87 0.74↓** 1.12 0.95 
Polyunsaturated Fatty Acid 
(n3 and n6) 
docosapentaenoate (n3; 22:5n3) 0.64↓** 0.68↓** 1.30 0.94 
docosahexaenoate (22:6n3) 0.74↓* 0.83 1.18 1.02 
linoleate (18:2n6) 0.86 0.80↓* 1.20 0.92 
dihomo-linolenate (20:3n3 or n6) 0.76↓* 0.74↓** 1.20 0.97 
arachidonate (20:4n6) 0.78↓** 0.86↓* 1.13 0.97 
adrenate (22:4n6) 0.64↓* 0.68↓* 1.86 1.23 
docosapentaenoate (n6; 22:5n6) 0.79↓* 0.77↓* 1.20 1.04 
docosadienoate (22:2n6) 0.84 0.67↓** 1.17 0.89 
dihomo-linoleate (20:2n6) 0.73 0.66↓* 1.24 0.90 
Fatty Acid, Branched 
13-methylmyristate 0.90 0.63↓** 1.33 0.99 
15-methylpalmitate 0.93 0.66↓** 1.31 0.97 
17-methylstearate 0.97 0.70↓** 1.18 0.96 
Fatty Acid, Dicarboxylate 
adipate 1.06 1.12↑** 1.02 1.02 
hexadecanedioate 0.87 0.91 1.70↑* 0.93 
octadecanedioate 0.87 0.80↓* 1.44 0.83 
docosadioate 1.08 1.44 0.79↓* 1.29 
Fatty Acid, Amino 2-aminooctanoate 1.06 1.22 0.78↓* 1.00 




Fatty Acid Metabolism  
(Acyl Carnitine) 
acetylcarnitine 1.08 0.80↓* 1.13 0.85 
3-hydroxybutyrylcarnitine 2.38 0.86 1.27 0.63↓* 
hexanoylcarnitine 1.02 0.80↓* 1.18 0.94 
octanoylcarnitine 0.97 0.76↓* 1.21 1.00 
decanoylcarnitine 0.97 0.75↓* 1.39 1.08 
myristoleoylcarnitine 1.00 0.75↓* 1.32 0.85 
suberoylcarnitine 1.73↑* 0.98 4.08 3.07 
arachidoylcarnitine 0.88 1.09 0.73↓** 1.06 
arachidonoylcarnitine 1.14 1.11 1.31↑* 1.05 
adrenoylcarnitine 1.06 1.10 1.30 1.13 
behenoylcarnitine 0.81 1.18 0.65↓** 1.04 
dihomo-linolenoylcarnitine 1.05 1.03 1.31↑*** 1.05 
lignoceroylcarnitine  0.84↓* 1.12 0.71↓** 0.90 
margaroylcarnitine 1.01 0.84↓* 1.09 1.06 
cerotoylcarnitine 0.91 1.11 0.89↓* 0.92 
Carnitine Metabolism deoxycarnitine 0.92↓* 0.93 1.04 1.00 
Ketone Bodies acetoacetate 2.08 1.50 2.13 0.67↓* 
Fatty Acid, Monohydroxy 
alpha-hydroxycaproate 4.85 1.00 12.46↑** 0.94 
2-hydroxypalmitate 0.85 0.82↓* 1.13 0.89 
3-hydroxylaurate 0.78 0.74↓* 1.33 0.87 
3-hydroxymyristate 0.91 0.77↓* 1.27 0.83 
16-hydroxypalmitate 0.96 0.92 1.38↑* 0.98 
9-hydroxystearate 1.09 0.72↓** 1.29 0.97 
Fatty Acid, Dihydroxy 12,13-DiHOME 1.12 1.36↑* 1.18 0.88 
Endocannabinoid 
oleoyl ethanolamide 0.90 0.77↓* 1.13 0.95 
palmitoyl ethanolamide 0.98 0.81↓* 1.15 1.04 
arachidonoyl ethanolamide 1.24 0.94 1.77↑* 1.18 
N-oleoyltaurine 0.49↓** 0.94 1.03 1.74 
N-palmitoyltaurine 0.56↓** 1.12 1.46 1.48 
Phospholipid Metabolism 
choline phosphate 1.97 2.72 0.65↓* 1.49 
1-linoleoyl-2-linolenoyl-GPC 1.63 2.11↑* 1.22 1.10 
1-palmitoyl-2-palmitoleoyl-GPC 1.08 0.98 1.30 1.48↑* 
docosahexaenoylcholine 1.25 0.98 1.08 0.82↓* 
Lysolipid 
2-palmitoleoyl-GPC 0.95 1.31 1.95↑* 2.65↑** 
1-palmitoyl-GPG 0.83 0.90 1.35 2.05↑* 
1-oleoyl-GPG 0.85 0.75↓* 0.84 2.12 




1-pentadecanoylglycerol 0.71↓* 0.72↓* 1.02 1.10 
1-palmitoylglycerol 0.76↓** 0.86 1.07 1.03 
2-palmitoylglycerol  0.77↓* 0.79↓* 1.05 1.01 
1-margaroylglycerol 0.80 0.85 1.46 0.63↓* 
1-oleoylglycerol 0.85↓* 0.88 0.90 0.90 
2-oleoylglycerol 0.81 0.92 0.80↓* 1.05 
1-dihomo-linolenylglycerol 0.81↓* 0.77↓* 1.17 0.99 
Diacylglycerol 
diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2] 1.83 1.77 5.07 8.03↑** 
diacylglycerol (14:0/18:1, 16:0/16:1) [1] 1.13 1.29 2.39 3.42↑* 
diacylglycerol (14:0/18:1, 16:0/16:1) [2] 1.17 1.13 1.99 2.70↑* 
linoleoyl-linolenoyl-glycerol (18:2/18:3) [1] 1.12 1.71 2.28↑** 0.93 
palmitoyl-myristoyl-glycerol (16:0/14:0) [2] 2.14 1.36 2.50 3.84↑** 
palmitoyl-palmitoyl-glycerol (16:0/16:0) [2] 1.08 0.91 1.88↑* 1.91 
palmitoyl-linolenoyl-glycerol (16:0/18:3) [2] 1.10 1.35 4.44↑** 1.41 
Sphingolipid Metabolism 
N-behenoyl-sphingadienine (d18:2/22:0) 0.92 0.99 0.91↓* 0.87↓** 
myristoyl dihydrosphingomyelin (d18:0/14:0) 1.13 0.96 1.26↑* 1.01 
sphingomyelin (d18:1/18:1, d18:2/18:0) 1.01 0.98 1.19↑* 0.97 
sphingomyelin (d18:1/20:0, d16:1/22:0) 0.95 1.00 0.91↓* 0.93 
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1) 0.98 0.98 0.91↓* 0.94 
N-palmitoyl-sphingosine (d18:1/16:0) 1.05 1.02 1.44↑* 1.05 
glycosyl-N-palmitoyl-sphingosine (d18:1/16:0) 1.03 0.97 0.91↓* 0.94 
sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2) 1.22 1.02 1.55↑** 0.98 
sphingomyelin (d18:2/24:2) 1.25 1.06 1.37↑* 1.02 
N-nervonoyl-hexadecasphingosine (d16:1/24:1) 1.09 0.91 1.22↑* 1.02 
sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2) 1.22 1.02 1.38↑* 0.99 
Sterol 3beta-hydroxy-5-cholestenoate 0.87 0.84↓* 1.08 0.93 
Steroid 
pregnenolone sulfate 0.85↓* 0.93 1.04 1.14 
21-hydroxypregnenolone disulfate 0.99 1.08 1.52↑* 0.93 
5alpha-pregnan-3beta,20beta-diol monosulfate (1) 0.77↓* 0.94 1.09 1.05 
5alpha-pregnan-3beta,20alpha-diol monosulfate (2) 0.81↓* 0.89 0.96 1.10 
pregn steroid monosulfate 0.77↓*** 0.90 1.12 1.00 
pregnanediol-3-glucuronide 0.74↓** 1.00 1.18 1.11 
16a-hydroxy DHEA 3-sulfate 1.29 1.07 1.47↑** 1.06 
androstenediol (3beta,17beta) monosulfate (2) 1.12 1.04 1.20↑* 0.94 
androstenediol (3beta,17beta) disulfate (1) 1.13 1.01 1.21↑* 0.95 
androstenediol (3beta,17beta) disulfate (2) 1.05 1.00 1.26↑** 0.99 
5alpha-androstan-3alpha,17beta-diol monosulfate (1) 1.08 0.93 1.43↑** 1.02 
5alpha-androstan-3alpha,17beta-diol disulfate 0.73↓* 1.18 1.04 0.80 
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andro steroid monosulfate (1) 1.52 1.01 1.54↑* 1.18 
Primary Bile Acid 
Metabolism 
taurocholate 4.56 1.24 3.65↑* 2.30 
taurochenodeoxycholate 6.55 1.25 2.58 2.81↑* 
tauro-beta-muricholate 2.42 1.12 2.29↑* 2.16 
glycocholate glucuronide (1) 1.00 1.01 1.00 0.93↓* 
Secondary Bile Acid 
Metabolism 
glycodeoxycholate 0.97 4.27↑* 1.10↑* 1.37 
glycohyocholate 3.75↑* 1.29 1.94 1.55 
7-ketodeoxycholate 0.55↓** 1.26 1.01 1.04 
Ceramides 
ceramide (d18:1/14:0, d16:1/16:0) 1.09 0.93 1.22↑* 1.07 
ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0) 0.95 1.01 0.97 0.90↓* 
ceramide (d18:2/24:1, d18:1/24:2) 1.04 0.93 1.16 0.87↓* 
Fatty Acid Metabolism (Acyl 
Choline) 
linoleoylcholine 6.95 1.75 4.17 0.63↓* 
DHEA, Dehydroepiandrosterone; 12,13-DiHOME, 12,13-dihydroxy-9Z-octadecenoic acid; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; 
GPG, glycerophosphoglycerol. aMetabolites that were detected in plasma but non-significant (p>0.05) in dietary groups compared to respective baseline are not 
presented in this table. bValues presented are mean metabolite ratios/fold-changes. Statistically-significantly increased (↑) fold-changes are bolded and 
highlighted in red, and statistically-significantly decreased (↓) fold-changes are bolded and highlighted in blue (*p≤0.05; **p≤0.01; ***p≤0.001). 
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3.5  Differences in plasma amino acid metabolites following navy bean and/or rice bran 
consumption 
As indicated in Figure 3, aside from lipids, metabolites within the amino acid class were 
also significantly modulated by navy bean and/or rice bran consumption (Table 4, Figure 
5a,c,e). Compared to control at 4 weeks, navy bean consumption decreased 7 amino acid 
metabolites, including O-acetylhomoserine, phenylalanine, isovalerylcarnitine, 3-
hydroxyisobutyrate, methionine, methionine sulfoxide, and oxidized cysteine-glycine dipeptide 
(0.53- to 0.84-fold difference), and increased 6-oxopiperidine-2-carboxylate (1.87-fold 
difference) (Table 4). Rice bran consumption decreased 7 amino acids compared to control at 4 
weeks, including 3 histidine metabolites (0.28- to 0.57-fold difference), isovalerylglycine, 
isovalerylcarnitine, 5-hydroxyindoleacetate, and N-formylmethionine (Table 4). The 
consumption of navy bean + rice bran significantly modulated 4 amino acid metabolites 
compared to control, with a 3.11-fold difference increase in gentisate, and significant decreases 
in betaine, 4-methyl-2-oxopentanoate, and 3-methyl-2-oxovalerate (Table 4).  
Compared to baseline, navy bean consumption for 4 weeks increased 7 amino acids, 
including pipecolate (2.86-fold change), S-methylcysteine (2.12-fold change), S-methylcysteine 
sulfoxide (2.19-fold change), along with 2,3-dihydroxy-2-methylbutyrate, 2-hydroxy-3-
methylvalerate, N-acetyl-3-methylhistidine, and N-delta-acetylornithine. Five amino acids were 
decreased following navy bean consumption compared to baseline (N-acetylglycine, kynurenate, 
methylsuccinylcholine, N-alpha-acetylornithine, N-acetylcitrulline) (Table 5, Figure 5b,d,f). 
Rice bran consumption for 4 weeks compared to baseline resulted in an increase in 24 amino 
acids across multiple metabolic pathways, among which included 5 phenylalanine and tyrosine 
metabolites (1.11- to 2.32-fold change), 3 urea cycle metabolites (1.09- to 1.23-fold change), and 
3 methionine and cysteine metabolites (1.20- to 3.34-fold change). The navy bean + rice bran 
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combination group had limited effects on amino acid metabolites compared to baseline (1 
increased and 1 decreased). Interestingly, the control group also increased 6 and decreased 2 
amino acids. 
 
Table 4       Other Modulated Plasma Metabolites Following Navy Bean and/or Rice Bran    
                    Consumption for 4 Weeks Compared to Controla 





Navy Bean + 
Rice Bran 
Amino Acids 
Gly, Ser & Thr Metabolism 
betaine 0.93 0.93 0.85↓** 
O-acetylhomoserine 0.53↓* 0.66 1.58 
His Metabolism 
3-methylhistidine 0.87 0.28↓* 0.39 
N-acetyl-1-methylhistidine 0.96 0.53↓* 0.72 
trans-urocanate 0.91 0.57↓** 0.99 
Lys Metabolism 6-oxopiperidine-2-carboxylate 1.87↑** 1.49 1.49 
Phe & Tyr Metabolism 
phenylalanine 0.86↓** 1.00 0.95 
gentisate 1.96 1.48 3.11↑* 
Trp Metabolism 5-hydroxyindoleacetate 0.67 0.67↓* 0.98 
Leu, Ile & Val Metabolism 
4-methyl-2-oxopentanoate 0.96 0.96 0.79↓* 
isovalerylglycine 0.68 0.34↓** 0.54 
isovalerylcarnitine 0.67↓* 0.62↓** 0.72 
3-methyl-2-oxovalerate 0.97 0.94 0.78↓* 
3-hydroxyisobutyrate 0.61↓* 1.01 0.74 
Met, Cys, SAM and Taurine 
Metabolism 
methionine 0.84↓** 0.91 0.95 
N-formylmethionine 0.99 0.85↓** 1.07 
methionine sulfoxide 0.77↓* 0.86 0.86 




gamma-glutamyl-epsilon-lysine 1.25 1.30 1.37↑* 
Carbohydrate 




urate 0.89 0.84 0.83↓* 
Purine Metabolism, Adenine adenosine 2.19 0.09↓* 0.23 
Pyrimidine Metabolism, 
Cytidine 
cytidine 1.20 0.35↓* 0.77 
Cofactors/Vitamins 
Nicotinate & Nicotinamide 
Metabolism 
1-methylnicotinamide 0.58↓** 0.79 1.03 
trigonelline (N'-methylnicotinate) 4.44↑* 1.51 1.39 
Hemoglobin & Porphyrin 
Metabolism 
heme 0.79 0.56↓** 0.89 
Vitamin B6 Metabolism pyridoxal 1.47 3.35↑** 1.63 
Phytochemicals/Other 
Benzoate Metabolism 
3-methyl catechol sulfate 1.82 0.43 0.36↓* 




2-isopropylmalate 1.01 0.79↓* 0.98 
N-acetylalliin 0.51↓* 0.72 0.53 
erythritol 0.85↓* 0.92 0.93 
saccharin 0.96 0.21↓** 0.49 
theanine 1.00 1.00 8.11↑* 
Drug omeprazole 0.47↓* 0.47↓* 0.47↓* 
Chemical N-methylpipecolate 1.89↑* 1.94 0.98 
Cys, cysteine; Gly, glycine; His, histidine; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, 
phenylalanine; SAM, S-adenosyl methionine; Ser, serine; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine. 
a Metabolites that were detected in plasma but non-significant (p>0.05) in dietary groups compared to control are not 
presented in this table. b Values presented are mean metabolite ratios/fold-differences. Statistically-significantly 
increased (↑) fold-differences are bolded and highlighted in red, and statistically-significantly decreased (↓) fold-
differences are bolded and highlighted in blue (*p≤0.05; **p≤0.01). 
 
Table 5     Other Modulated Plasma Metabolites Following Navy Bean and/or Rice Bran 
                  Consumption for 4 Weeks Compared to Baselinea 











Gly, Ser & Thr Metabolism 
glycine 1.08 1.03 1.18↑* 1.03 
N-acetylglycine 0.77↓* 0.76↓** 1.18 0.93 
dimethylglycine 1.29 0.93 1.65↑* 0.93 
serine 1.13 0.94 1.79↑** 0.89 
Ala & Asp Metabolism 
N-acetylasparagine 1.03 0.87 1.31↑* 1.10 
N-acetylaspartate 1.05 1.02 0.89↓* 1.00 
Glu Metabolism glutamine 1.02 1.03 1.12↑** 0.99 
His Metabolism 
histidine 1.04 0.99 1.14↑* 1.03 
N-acetyl-3-methylhistidine 1.11 1.79↑* 0.86 1.00 
Lys Metabolism 
lysine 1.11 1.00 1.12↑* 1.04 
pipecolate 1.85 2.86↑* 1.52 1.53 
Phe & Tyr Metabolism 
phenylalanine 1.07 0.97 1.11↑* 1.04 
tyrosine 1.18↑* 0.94 1.13 1.08 
N-acetyltyrosine 1.20 0.99 1.50↑* 1.11 
4-hydroxyphenylpyruvate 1.14 1.05 1.63↑* 0.96 
3-(4-hydroxyphenyl) lactate 1.00 0.98 1.05 1.17↑* 
homovanillate 1.49 1.19 2.32↑** 1.02 
N-formylphenylalanine 1.15↑* 1.96 1.16 1.14 
5-bromotryptophan 1.08 1.06 1.15↑* 1.01 
Trp Metabolism 
indolepropionate 1.91↑* 1.60 1.11 1.12 
kynurenate 1.04 0.87↓* 1.15 1.01 
5-hydroxyindoleacetate 1.47↑* 0.97 0.91 1.08 
thioproline 1.61 1.03 4.29↑** 0.73 
Leu, Ile & Val Metabolism 
leucine 1.07 0.94 1.14↑* 1.01 
isovalerylglycine 3.83↑** 1.57 1.25 0.86 
2,3-dihydroxy-2-
methylbutyrate 
1.27 1.57↑* 0.83 1.09 
2-hydroxy-3-methylvalerate 0.98 1.32↑* 0.95 1.00 
N-acetylvaline 1.41 0.97 1.32 0.76↓* 
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methylsuccinoylcarnitine (1) 1.09 0.85↓* 1.10 1.06 
Met, Cys, SAM and Taurine 
Metabolism 
methionine sulfone 1.27 0.95 3.34↑** 0.85 
methionine sulfoxide 1.27 0.88 1.48↑* 0.98 
cystathionine 2.85↑** 1.56 1.81 1.35 
cysteine 1.02 0.97 1.20↑* 1.03 
S-methylcysteine 1.31 2.12↑** 1.31 1.33 
S-methylcysteine sulfoxide 1.34 2.19↑** 1.62 1.79 
cysteine sulfinic acid 0.76↓* 0.87 1.00 1.21 
Urea cycle; Arg & Pro 
Metabolism 
arginine 0.99 1.01 0.92↓* 1.07 
proline 1.02 0.98 1.20↑** 1.07 
citrulline 1.09 1.04 1.23↑* 0.94 
dimethylarginine (SDMA + 
ADMA) 
1.01 0.98 1.09↑* 1.01 
N-delta-acetylornithine 1.01 1.33↑* 0.94 1.10 
N-alpha-acetylornithine 1.21 0.81↓* 1.04 1.21 
N-acetylcitrulline 1.34 0.80↓* 1.02 1.65 
Creatine Metabolism 
creatinine 0.97 0.98 1.06↑** 1.00 
guanidinoacetate 1.19 1.09 1.58↑** 1.04 
Polyamine Metabolism spermidine 3.20 2.59 0.73↓* 2.96 
Glutathione Metabolism 
cysteinylglycine 1.03 1.13 1.64↑** 1.19 





gamma-glutamylglutamate 1.16 0.93 2.17↑*** 0.86 
gamma-glutamylglutamine 1.02 1.00 1.45↑*** 0.98 
gamma-glutamylhistidine 1.20 0.94 1.53↑* 1.16 
gamma-glutamylleucine 1.05 1.04 1.36↑** 0.96 
gamma-glutamyl-alpha-lysine 1.09 0.98 1.21↑* 1.07 
gamma-glutamyl-epsilon-
lysine 
0.84↓* 1.00 1.09 1.34 
gamma-
glutamylphenylalanine 
1.06 1.02 1.68↑** 1.44 
gamma-glutamylthreonine 1.46 1.05 2.27↑* 0.91 
gamma-glutamyltryptophan 1.02 0.95 1.32↑* 0.90 
gamma-glutamyltyrosine 1.12 0.93 1.16 1.23↑* 
gamma-glutamylvaline 1.04 1.02 1.28↑* 1.02 
Fibrinogen Cleavage Peptide DSGEGDFXAEGGGVR 3.04 1.00 1.36 5.15↑* 
Acetylated Peptides 
phenylacetylglutamate 1.00 1.33 0.91 1.87↑* 




and Pyruvate Metabolism 
glucose 0.96 1.05 0.91↓* 1.08 
glycerate 0.89 0.94 0.80↓** 1.05 
Pentose Metabolism 
arabitol/xylitol 0.99 1.00 1.17↑** 1.02 
arabonate/xylonate 0.86 1.08 0.84↓* 1.13 
Disaccharides and 
Oligosaccharides 
sucrose 0.77 1.89 0.80 2.60↑* 
Aminosugar Metabolism 
erythronate 0.99 1.01 0.90↓* 0.99 
N-acetylglucosamine/N-
acetylgalactosamine 
1.04 1.00 1.18↑** 0.99 
Energy 
 TCA Cycle 
citrate 1.01 0.97 1.09↑** 0.97 
fumarate 2.65 2.37 0.41↓** 1.41 
Nucleotide 






N1-methylinosine 1.05 0.90 1.36↑** 0.97 
allantoin 0.82↓** 0.76↓*** 0.71↓*** 1.07 




0.82↓* 1.19 1.36 1.10 
N6-
carbamoylthreonyladenosine 
1.05 1.04 1.23↑* 1.05 
Purine Metabolism, Guanine 
containing 
guanosine 15.48↑* 0.93 2.95 1.06 
Pyrimidine Metabolism, 
Orotate containing 
dihydroorotate 1.40 2.25 2.58↑* 0.93 
Pyrimidine Metabolism, 
Uracil containing 
uridine 1.14 0.96 1.27↑* 1.00 
N-acetyl-beta-alanine 1.06 0.93 1.18↑* 1.01 
Pyrimidine Metabolism, 
Cytidine containing 
cytidine 3.46 3.67 0.65↓* 3.02 
Cofactors/Vitamins 
 




2.42 7.65↑** 2.25 1.15 
Pantothenate and CoA 
Metabolism 
pantothenate 1.05 0.92 1.32↑** 1.00 
Ascorbate and Aldarate 
Metabolism 
ascorbate (Vitamin C) 1.25 1.43 3.55 1.99↑* 
Tocopherol Metabolism alpha-CEHC sulfate 0.90 1.60 2.11 0.70↓* 
Hemoglobin and Porphyrin 
Metabolism 
bilirubin (Z,Z) 1.46 1.34 2.20↑** 0.93 
bilirubin (E,E) 0.69↓** 0.64↓*** 1.06 1.03 
bilirubin (E,Z or Z,E) 1.19 1.20 1.70↑** 0.93 






1.88 1.34 3.05↑* 3.82 
Xanthine Metabolism 
caffeine 5.68 0.50↓* 3.94 9.59↑* 
paraxanthine 2.65↑* 0.65↓* 1.61 2.73↑* 
theophylline 2.60 0.68↓* 1.33 3.30↑* 
1,3-dimethylurate 1.25 0.79↓* 1.22 1.29 
1,7-dimethylurate 2.96 0.71↓* 1.70 4.29↑** 
1-methylxanthine 1.17 0.97 1.08 2.50↑* 
3-methylxanthine 2.24 0.64↓* 2.03 4.32↑* 
5-acetylamino-6-amino-3-
methyluracil 
7.28↑* 0.60↓* 3.06 10.85↑* 
Tobacco Metabolite cotinine 0.87↓* 1.00 1.00 1.00 
Food Component/Plant 
retinal 0.73↓* 1.21 1.04 1.65 
alliin 1.88 1.17 3.34↑* 1.12 
N-acetylalliin 1.98↑* 1.09 1.20 0.82↓* 
ferulic acid 4-sulfate 1.11 4.62↑* 1.23 0.91 
stachydrine 1.44 3.46 0.60↓* 2.08 
4-allylphenol sulfate 9.19↑* 2.54 4.66 4.47↑* 
methyl glucopyranoside 
(alpha + beta) 
1.55 1.67 1.00 2.55↑* 
4-vinylguaiacol sulfate 1.12 20.17↑* 1.64 2.40 
umbelliferone sulfate 6.74↑* 0.95 1.00 0.86 
2-keto-3-deoxy-gluconate 1.02 1.02 1.46↑* 1.32 
3,4-methyleneheptanoate 0.82 1.13 1.24 0.73↓** 
Drug/Plant omeprazole 2.14↑* 1.00 1.00 1.00 
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salicylate 1.22 1.25 2.74↑* 3.03 
S-carboxymethyl-L-cysteine 1.78 1.00 3.14↑* 1.13 
Chemical 
dimethyl sulfone 1.20 1.54↑* 1.28 1.72↑** 
ectoine 1.60 23.49↑* 3.15 2.30 
N-methylpipecolate 0.79↓** 1.02 1.46↑*** 0.96 
4-hydroxychlorothalonil 1.00 0.92↓* 1.12↑* 0.95 
Alpha-CEHC, 2, 5, 7, 8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman; ADMA, asymmetric dimethylarginine; 
Ala, alanine; Arg, arginine; Asp, aspartate; Cys, cysteine; Glu, glutamate; Gly, glycine; His, histidine; Ile, 
isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, phenylalanine; Pro, proline; SAM, S-adenosyl 
methionine; SDMA, symmetric dimethylarginine; Ser, serine; TCA, tricarboxylic acid; Thr, threonine; Trp, 
tryptophan; Tyr, tyrosine; Val, valine. aMetabolites that were detected in plasma but non-significant (p>0.05) in 
dietary groups compared to respective baseline are not presented in this table. bValues presented are mean 
metabolite ratios/fold-changes. Statistically-significantly increased (↑) fold-changes are bolded and highlighted in 








Figure 5. Cytoscape pathway visualizations of amino acid metabolites modulated by Navy Bean, Rice Bran, 
or Navy Bean + Rice Bran consumption. Amino acid metabolites modulated by Navy Bean, Rice Bran, or Navy 
Bean + Rice Bran consumption for 4 weeks compared to control (a,c,e) or compared to respective baseline (b,d,f), 
respectively. Nodes in red and blue represent significantly increased and decreased metabolites, respectively, 
compared to control at 4 weeks or compared to baseline. Node diameters are proportional to the magnitude of the 
fold-difference. Numbers within nodes represent pathway enrichment scores. 
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3.6  Phytochemicals detected and modulated following navy bean and/or rice bran 
consumption 
Phytochemicals (and other exogenous compounds) represented the third largest metabolic 
grouping modulated by navy bean and/or rice bran consumption (Figure 3). Compared to 
control, navy bean consumption increased the phytochemicals 4-vinylphenol sulfate (2.22-fold 
difference) and N-methylpipecolate (1.89-fold difference), and decreased N-acetylalliin, 
erythritol, and the drug compound omeprazole (Table 4, Figure 6a,c,e). Rice bran consumption 
decreased 3 phytochemicals and exogenous chemicals compared to control, including 2-
isopropylmalate, saccharin, and omeprazole. Navy bean + rice bran consumption increased 
theanine (8.11-fold difference) and decreased 3-methyl catechol sulfate and omeprazole, 
compared to control. 
Compared to baseline, navy bean consumption for 4 weeks decreased 8 phytochemicals 
and exogenous compounds, including 7 xanthine metabolites (0.50- to 0.79-fold change), and 4-
hydroxylchlorothalonil (0.92-fold change) (Table 5, Figure 6b,d,f). Several phytochemicals and 
exogenous compounds were also increased in the navy bean group compared to baseline with 
large magnitude fold-changes, including ferulic acid 4-sulfate (4.62-fold change), 4-
vinylguaiacol sulfate (20.17-fold change), dimethyl sulfone (1.54-fold change), and ectoine 
(23.49-fold change). Phytochemicals and exogenous compounds increased following rice bran 
consumption compared to baseline included the benzoate metabolite 2-hydroxyhippurate (3.05-
fold change), alliin (3.34-fold change), salicylate (2.74-fold change), S-carboxymethyl-L-
cysteine (3.14-fold change), 2-keto-3-deoxy-gluconate, N-methylpipecolate, and 4-
hydroxychlorothalonil. One food metabolite, stachydrine, was decreased in rice bran group. Ten 
phytochemicals and exogenous compounds were increased in the navy bean + rice bran group 
compared to baseline, including 7 xanthine metabolites (2.50- to 10.85-fold change), allylphenol 
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sulfate (4.47-fold change), methyl glucopyranoside (2.55-fold change), and dimethyl sulfone 
(1.72-fold change), and 2 phytochemicals were decreased (N-acetylalliin and 3,4-
methyleneheptanoate). Phytochemicals and exogenous compounds increased in the control group 
include 4-allylphenol sulfate (9.19-fold change), umbelliferone sulfate (6.74-fold change), 
paraxanthine (2.65-fold change), 5-acetylamino-6-amino-3-methyluracil (7.28-fold change), N-
acetylalliin (1.98-fold change), and omeprazole (2.14-fold change), and decreased 







Figure 6. Cytoscape pathway visualizations of phytochemicals and exogenous metabolites metabolites 
modulated by Navy Bean, Rice Bran, or Navy Bean + Rice Bran consumption. Phytochemicals and exogenous 
metabolites modulated by Navy Bean, Rice Bran, or Navy Bean + Rice Bran consumption for 4 weeks compared to 
control (a,c,e) or compared to respective baseline (b,d,f), respectively. Nodes in red and blue represent significantly 
increased and decreased metabolites, respectively, compared to control at 4 weeks or compared to baseline. Node 




3.7  Other metabolic pathways modulated by navy bean and/or rice bran consumption 
In comparison to lipids, amino acids, and phytochemicals, fewer metabolites from the 
cofactor/vitamin, carbohydrate, peptide, nucleotide, energy pathways were significantly 
modulated by navy bean and/or rice bran consumption (Figure 3). Yet large magnitude fold-
changes/differences from these pathways are of possible health importance and may also 
represent novel dietary biomarkers of intake. Navy bean consumption compared to control 
significantly increased the vitamin B3 metabolite trigonelline (4.44-fold difference), and 
decreased the relative abundances of the carbohydrate metabolite ribitol and the nicotinamide 
metabolite 1-methylnicotinamide (Table 4). In the rice bran group, a large 3.35-fold difference 
increase in pyridoxal (vitamin B6) was observed compared to control at 4 weeks. Several 
metabolites from the nucleotide and cofactor/vitamin metabolic pathways were decreased 
following rice bran consumption compared to control, including adenoside, cytidine, and heme. 
In the navy bean + rice bran group, an increase in the peptide gamma-glutamyl amino acid, and 
decreases in ribitol, urate, 3-methyl catechol sulfate, and omeprazole, were determined. 
Compared to baseline, a significant 7.65-fold change increase in trigonelline was also 
observed in the navy bean group (Table 5). Navy bean consumption also decreased the 
hemoglobin metabolite bilirubin (E,E isomeric forms) (0.69-fold change) compared to baseline, 
but had no to limited modulatory effects on carbohydrate, nucleotide, peptide, or energy pathway 
metabolites. Rice bran consumption increased 4 cofactors/vitamins compared to baseline, 
including a 3.96-fold change increase in pyridoxal (vitamin B6), as well as bilirubin (Z, Z; E, Z; 
and Z, E isomeric forms), and pantothenate. In addition, 6 nucleotides were increased by rice 
bran consumption, with the largest fold-changes observed for hypoxanthine (3.15-fold change) 
and dihydroorotate (2.58-fold change), while 2 nucleotides were decreased (0.65- to 0.71-fold 
change). Rice bran consumption compared to baseline also increased 2 (1.17- to 1.18-fold 
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change) and decreased 4 (0.41- to 0.91-fold change) carbohydrates, and 9 peptides (gamma-
glutamyl amino acids; 1.21- to 2.27-fold change). However, limited effects were observed on 
energy metabolites following rice bran consumption compared to baseline. Consumption of navy 
bean + rice bran for 4 weeks compared to baseline increased ascorbate (vitamin C) (1.99-fold 
change), and decreased the tocopherol metabolite alpha-CEHC sulfate (0.70-fold change). Three 
peptide metabolites were also increased by navy bean + rice bran consumption (gamma-
glutamyltyrosine, fibrinogen cleavage peptide, and phenylacetylglutamate); however, there were 
limited modulatory effects on carbohydrate, nucleotide, and energy pathway metabolites. The 
control group modulated 4 nucleotides (2 increased, 2 decreased), decreased 2 peptides, and 
decreased the hemoglobin metabolite bilirubin (E, E isomer) compared to baseline, but had no 
effects on carbohydrates, energy pathway metabolites. 
 
3.8  Plasma metabolites detected in the food metabolome 
Of the 854 metabolites identified in plasma, 321 were also detected in the food 
metabolome in a parent or intermediate form (267 from navy bean, 300 from rice bran) (data not 
shown). For navy bean, food metabolites detected with high relative abundance in plasma (fold 
change/difference >2) included trigonelline (4.44-fold difference; 7.65-fold change), ferulic acid 
4-sulfate (4.62-fold change), pipecolate (2.86-fold change), and S-methylcysteine (2.12-fold 
change), and S-methylcysteine sulfoxide (2.19-fold change). Rice bran metabolites detected with 
high relative abundance in plasma include methionine sulfone (3.34-fold change), alpha-
hydroxycaproate (12.46-fold change), linoleoyl-linolenoyl-glycerol (2.28-fold change), 
palmitoyl-linolenoyl-glycerol (4.44-fold change), pyridoxal (3.35-fold difference; 3.96-fold 
change), 2-hydroxyhippurate (3.05-fold change), salicylate (2.74-fold change), gamma-
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glutamylglutamate (2.17-fold change), gamma-glutamylthreonine (2.27-fold change), 








4.1  Plasma metabolome of children with aberrant cholesterol and correlations with 
serum lipids in the prediction of cardiovascular disease risk 
Our study is the first to characterize the plasma metabolome of children with aberrant 
cholesterol and examine correlations between plasma metabolites and serum lipid levels. We 
determined that 235 plasma metabolites (almost a third of the plasma metabolome) were 
correlated with serum lipids, and a subset of 27 metabolites to be strongly-correlated with serum 
TG (rs ≥0.60; p≤0.0001). These findings generate insight with both clinical and functional 
relevance for capturing health status and improving CVD risk assessment in children. 
Elevated serum total or LDL-cholesterol are valuable clinical predictors of 
atherosclerosis and CVD risk (33). However, individuals who develop CVD do not always 
present with these established risk factors, which complicates early disease detection and 
intervention (34). Dysregulated lipid metabolism has been shown to underlie CVD progression, 
and several key small-molecule metabolites in blood have been associated with childhood 
obesity (35), as well as dyslipidemia (18, 36), type II diabetes (37-39), and insulin resistance 
(40), and coronary heart disease (41) in adults and/or experimental animals. In our study, almost 
70% of diacylglycerols identified in plasma were strongly positively correlated with serum TG. 
Diacylglycerols are a precursor in the synthesis of TG, as well as a digestive product of dietary 
TG, and high intracellular concentrations have been implied as a contributing mechanism 
towards insulin resistance (42). Additionally, we observed significant negative correlations 
between several plasma plasmalogens and serum TG, including 1-(1-enyl-palmitoyl)-2-oleoyl-
glycerophosphocholine (rs = -0.6806; p≤0.0001), 1-(1-enyl-palmitoyl)-2-palmitoyl- 
glycerophosphocholine (rs = -0.5075; p=0.0011), and 1-(1-enyl-palmitoyl)-2-linoleoyl- 
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glycerophosphocholine (rs = -0.3464; p=0.0332). Plasmalogens are subset of membrane 
glycerophospholipids with roles in cholesterol trafficking, maintenance of cellular membrane 
integrity, and may act as endogenous plasma antioxidants (43). Decreased plasmalogen levels 
have been observed in patients with metabolic syndrome and type II diabetes in conjunction with 
increased lipid peroxidation and TG levels (44). We further determined 3 phospholipid 
metabolites to be strongly positively associated with serum TG, and 8 phospholipids were in the 
top 10% of metabolites elevated in plasma compared to all other metabolites. Additionally, 34 
sphingolipids were determined to be positively correlated with serum total and LDL-cholesterol, 
and 12 sphingolipids were in the top 10% of metabolites elevated in plasma. While these lipids 
are integral structural components of biological membranes, they can also mediate cellular 
processes including oxidation and inflammation, contributing to atherosclerosis (45, 46). The 
role of sphingolipids in the pathogenesis of cardiometabolic diseases is well-documented. 
Elevated plasma sphingolipids have been observed in adults with diabetes (47), and more 
recently, altered sphingolipid and glycerophospholipid metabolism have also been observed with 
atherosclerotic progression in apolipoprotein E-deficient mice (46).  
Aside from lipids, dysregulations in other metabolic pathways may also be relevant to 
CVD risk and of interest as novel targets of intervention. Several plasma branched-chain amino 
acids (leucine, isoleucine, butyrylcarnitine, and propionylcarnitine) were loosely correlated with 
serum TG in our study (rs = 0.356 to 0.4217; p <0.05). The relative abundance of the branched-
chain amino acids leucine, isoleucine, and valine were also in the top 10% of all plasma 
metabolites identified. Elevated levels of branched-chain amino acids in blood have consistently 
been associated with metabolomic profiles of obesity in children (35, 40), and with diabetes and 
coronary artery disease in adults (33, 39, 48). Furthermore, lactate, an end product of glycolysis 
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and a gluconeogenic substrate (49), was determined to be positively associated with serum TG (rs 
= 0.5688, p=0.0002). High blood lactate levels have previously been associated with carotid 
atherosclerosis in adults (50), and in-hospital mortality in adults with pulmonary embolism (51). 
Integrating the plasma metabolome profiles of children with aberrant cholesterol with standard 
serum lipid panel data may be valuable in enhancing diagnostic sensitivity to improve CVD risk 
detection. 
 
4.2  Modulation of the plasma metabolome by navy bean and rice bran consumption 
Using a non-targeted metabolomics approach, we demonstrated that navy bean and/or 
rice bran consumption for 4 weeks significantly modulated the plasma metabolome of children 
with abnormal cholesterol. Lipid metabolites represented 46% of total metabolites identified, and 
significant changes determined for 18 plasma lipids in the navy bean group and 10 plasma lipids 
for the rice bran group compared to control, and 48 lipids in the navy bean group and 40 in the 
rice bran group compared to baseline, support the hypothesis that consumption of these foods 
impact blood lipid metabolism with implications for reducing CVD risk in children. The findings 
in this paper advance upon previous efforts whereby navy beans and/or rice bran demonstrated 
total and LDL-cholesterol-lowering properties (52, 53), as well as increasing HDL-cholesterol in 
children, adults and/or experimental animals (21, 25-29). 
 
4.2.1 Modulations in plasma lipid metabolites and cardiovascular disease risk 
 
Distinct subgroups of lipid metabolic pathways were differentially altered by 
consumption of navy bean and/or rice bran. Compared to the control group, navy bean 
consumption increased several acylcarnitines, lysolipids, and ceramides, whereas rice bran 
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consumption increased sphingolipids and ceramides, and navy bean + rice bran consumption 
increased lysolipids and phospholipids. Increased phospholipids were also determined for navy 
bean or rice bran consumption alone (1-palmitoleoyl-2-linolenoyl-glycerophosphocholine in the 
navy bean group, and 1-palmitoyl-2-oleoyl-glycerophosphocholine in the rice bran group), with 
high complementary pathway enrichment (score = 4.9) for 3 phospholipids in the navy bean + 
rice bran group. Lysolipids, sphingolipids, and phospholipids are critical components of cell 
membranes and important for many cell signalling processes that impact cholesterol absorption 
and bile acid secretion (54-56). Carnitines/acylcarnitines and ceramides are essential compounds 
for fatty acid metabolism and β-oxidation, and are derived from animal, plant, and/or microbial 
sources (57-59). However, increased acylcarnitines may also reflect inherited disorders in fatty 
acid and branched-chain amino acid catabolism associated with CVD, and increased ceramides 
can impact atherosclerosis and inflammation (57-59). The dual-functions of these lipids makes it 
difficult to discern the biological significance of their relative increase in plasma, and whether 
the net change is beneficial long-term. Additionally, since acylcarnitines are present in many 
foods at varying abundances, it is plausible that incorporation of navy beans and/or rice bran in 
the diet displaces animal-based foods that may be higher in saturated fats and cholesterol (60). 
Compared to baseline, navy bean consumption decreased multiple long-chain fatty acids and 
polyunsaturated fatty acids. Palmitate, a saturated long-chain fatty acid found from both animal 
and plant sources, has been associated with insulin resistance and an increased risk of CVD (59). 
Additionally, arachidonate, a polyunsaturated omega-6 fatty acid, is a precursor for many pro-
inflammatory prostaglandins and leukotrienes and decreased plasma levels following navy bean 
consumption may reduce inflammatory signally associated with metabolic risk (61). 
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Furthermore, modulations in several endogenous lipids are noteworthy for 
cardioprotection. Endocannabinoids, a group of endogenous bioactive lipids, were decreased in 4 
week navy bean plasma compared to baseline. Activation of cannabinoid (CB1) receptors by 
endocannabinoids has been implicated in the development of various cardiovascular disorders, 
including obesity, metabolic syndrome, insulin resistance, diabetes, and general inflammation 
(62). Further, N-linoleoylglycine, an endogenous compound increased following navy bean 
consumption, promotes the synthesis of anti-inflammatory eicosanoids, such as 15-deoxy-Δ13,14-
prostaglandin J2 and lipoxin A4, that protect against chronic inflammation (63). Given that 
chronic inflammation is intricately linked to CVD progression (64), investigation into how navy 
beans can reduce systemic inflammation could support their utility in chronic disease control. 
Navy bean consumption compared to baseline also increased the dihydroxy fatty acid metabolite 
12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME), an endogenous lipokine increased 
from brown adipose tissue following exposure to cold temperatures, that has been purported to 
be beneficial for metabolic disorders including obesity, diabetes, and hyperlipidemia (65). 
Additionally, significant increases in several primary and secondary bile acid metabolites 
following navy bean and/or rice bran consumption (compared to control and/or baseline) suggest 
dietary promotion of lipid solubilisation/absorption and biliary lipid secretion, which could be 
beneficial for growth in infants and young children, and warrants further investigation (66). 
 
4.2.2 Navy bean and rice bran-derived metabolites and cardiovascular disease risk 
Navy bean and/or rice bran consumption also increased multiple amino acids, 
phytochemicals, and cofactors/vitamins of dietary origin with nutritional and health importance. 
Navy beans are a rich source of the essential amino acid lysine, and several lysine-derived amino 
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acids and phytochemicals (6-oxopiperidine-2-carboxylate, pipecolate, N-methylpipecolate) were 
increased in plasma following navy bean consumption (21). Along with boosting nutritional 
status, lysine acts as a precursor in the synthesis of branched-chain fatty acids that are inversely 
associated CVD risk (57, 67). Multiple ferulic acid metabolites were also increased following 
navy bean intake compared to baseline, including ferulic acid 4-sulfate and 4-vinylguaiacol 
sulfate. Ferulic acid is a phytochemical with strong lipid anti-oxidant properties, and scavenges 
free radicals to prevent lipid peroxidation (68). Navy bean consumption compared to control and 
baseline also increased S-methylcysteine, along with its oxidized product, S-methylcysteine 
sulfoxide, both of which have antioxidant and antidiabetic functions with implications to 
attenuate inflammation and metabolic diseases (69, 70). Furthermore, the B-vitamin metabolite 
trigonelline increased 4.44-fold following navy bean consumption compared to control at 4 
weeks (also increased 7.65-fold in navy bean compared to baseline). Trigonelline may contribute 
to reducing levels of blood lipids and preventing type 2 diabetes through inhibiting lipase 
enzymes in the small intestine (71, 72).  
For rice bran consumption, a 3.35-fold increase in pyridoxal (vitamin B6) compared to 
control (and 3.96-fold compared to baseline) is considered beneficial, as pyridoxal inhibits lipid 
glycation processes that typically occur in atherosclerosis, and also plays a role in converting 
homocysteine (a CVD risk marker) into methionine (73, 74). The observed increase in plasma 
pyridoxal boosts our previous findings of improved vitamin B6 nutritional status reported for 
children that received rice bran compared to groups that did not receive rice bran (29). In 
addition, increased pyridoxal following rice bran consumption has been observed in adults as 
well (31, 75). Rice bran consumption also increased the relative abundance of salicylate 2.74-
fold compared to baseline. Salicylate, a phytochemical that plays a key function in plant defense 
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systems, is also the active compound in aspirin, which has been demonstrated to reduce risk of 
heart diseases (76). The increased relative abundance of diet-derived bioactive metabolites in 
plasma following consumption of these practical and cost-effective foods offers a mechanistic 
explanation for navy bean and/or rice bran in cholesterol-lowering and providing nutritional 
support in children, as well as providing a sustainable alternative to pharmaceutical prevention of 
CVD. Further, these exogenous compounds may represent dietary biomarkers for navy bean and 
rice bran that will aid in completing larger cohort and epidemiological investigations. 
 
4.3  Study Strengths and Limitations 
Our analysis included only metabolites that could be identified in the plasma metabolome 
(unknown compounds were not assessed). Limitations to this study include the absence of a 
normocholesterolemic population for the comparison of plasma metabolomes to children with 
aberrant cholesterol, as well as the pilot trial aspects, such as a small cohort size and short study 
duration. Although the small sample size presents a challenge  to true randomization, the sample 
size (n=38) is comparable to other nutritional metabolomics-based human studies (n=11 to 30 
total participants) (31, 77-79), and our study design analyzing both within- and between-group 
changes was a strength. All statistically significant fold-changes and fold-differences were 
included in our analyses, without indicating a magnitude cut-off, since findings from this pilot 
investigation could present valuable data to be verified in future cohorts. Moreover, since 
metabolites are downstream gene products, even small fold-changes/differences could be of 
biological significance. The tendency to select 1 or 2 compounds for future sample size estimates 
and power calculations warrants caution as this dietary intervention showed 10 to 20 metabolites 
differentially-affected in growing children that could be of equal importance (80). Further, the 
complexity in the metabolite profiles affected by diet as detected via this sensitive, non-targeted 
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metabolomics approach was with small doses of navy bean and/or rice bran (ranging 1.7 to 5.2% 
of the total caloric intake) (29), which indicates that small amounts of certain foods can be 
practically incorporated into the daily diets of children to influence underlying metabolic 
processes for CVD prevention. Interestingly, a number of significantly modulated metabolites 
were also observed in the control group over time, which was anticipated since these children 
still received a healthy study snack in their diet for 4 weeks. Further, we speculated that the 
fewer number of significant metabolites observed after 4 weeks of navy bean + rice bran 
consumption was dose-related. Investigations with larger daily intake doses of navy bean + rice 
bran as a combination warrants continued research attention to observe synergistic and 
complementary effects on the plasma metabolome. 
 
4.4  Conclusions 
Incorporation of navy beans and rice bran in the diet has great potential to improve the 
health of children at risk for CVD. This study utilized a non-targeted metabolomics approach to 
reveal a wide spectrum of plasma lipids, amino acids, and phytochemicals modulated by navy 
bean and/or rice bran consumption, all of which are of significance to impacting lipid profiles 
and overall nutritional status of children with early indices of dyslipidemia. Mitigating risk 
factors for CVD in children merits investigation with practical lifestyle interventions and this 
nutritional metabolomics approach offers great utility for the identification of dietary biomarkers 








Traditional self-reported methods for assessing dietary exposure are error-prone and 
poses a major challenge in the accurate identification of dietary components that mitigate disease 
risk (81, 82). Although navy beans and rice bran are foods abundant in bioactive phytochemicals 
and have demonstrated efficacy in preventing CVD and colorectal cancer, validated dietary 
biomarkers do not yet exist for navy bean or rice bran. Metabolomics is emerging as a powerful 
tool in the identification of dietary biomarkers (81). Using an integrated food and nutritional 
metabolomics approach, metabolites with high fold-increases in the plasma metabolome of 
children following 4-week consumption of navy bean or rice bran compared to control or 
individual baseline were assessed as candidate dietary biomarkers of navy bean and rice bran 
(e.g., trigonelline, pyridoxal). Additionally, non-targeted plasma, urine, and stool metabolomics 
performed on 29 adults following 4-week consumption of navy bean or rice bran helped to 
confirm the consistency and generalizability of these candidate compounds. Out of 854 
metabolites identified in biological samples, 138 and 175 metabolites had relevance to navy bean 
and rice bran, respectively, and were significantly increased in children and adults (p≤0.05). 
Candidate compounds were identified using a tiered system: (i) using food metabolomes to 
confirm the origin of metabolites detected in biological samples, (ii) ranking each metabolite 
based on presence in children and/or adults and the magnitude of the fold-change/difference, (iii) 
knowledge of previous detection in bean or rice products, and (iv) cost and practicality. A final 
list of 11 candidate dietary biomarkers included pipecolate, S-methylcysteine, S-methylcysteine 
sulfoxide, trigonelline, N-methyl pipecolate (for navy bean), pyridoxal, 2-hydroxyhippurate, 
apigenin, xanthurenate, chiro-inositol (for rice bran), and salicylate (both). Ongoing targeted 
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assays use isotope-labelled standards and triple-quadrupole liquid-chromatography mass-
spectrometry to confirm these candidate dietary biomarkers for navy bean or rice bran. The assay 
will need validation in future cohorts and will help to strengthen our knowledge of how these 
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